Mwanzo4559 • TYO
add
Zeria Pharmaceutical Co Ltd
Bei iliyotangulia
¥ 2,146.00
Bei za siku
¥ 2,129.00 - ¥ 2,161.00
Bei za mwaka
¥ 1,921.00 - ¥ 2,505.00
Thamani ya kampuni katika soko
114.15B JPY
Wastani wa hisa zilizouzwa
elfu 52.81
Uwiano wa bei na mapato
11.28
Mgao wa faida
2.09%
Ubadilishanaji wa msingi
TYO
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (JPY) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 20.97B | 14.11% |
Matumizi ya uendeshaji wa biashara | 12.52B | 14.20% |
Mapato halisi | 1.85B | -25.47% |
Kiwango cha faida halisi | 8.82 | -34.67% |
Mapato kwa kila hisa | — | — |
EBITDA | 4.39B | 8.29% |
Asilimia ya kodi ya mapato | 17.59% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (JPY) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 24.36B | 31.90% |
Jumla ya mali | 158.34B | 6.87% |
Jumla ya dhima | 69.77B | -3.36% |
Jumla ya hisa | 88.57B | — |
hisa zilizosalia | 44.08M | — |
Uwiano wa bei na thamani | 1.07 | — |
Faida inayotokana na mali | 4.06% | — |
Faida inayotokana mtaji | 4.89% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (JPY) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | 1.85B | -25.47% |
Pesa kutokana na shughuli | — | — |
Pesa kutokana na uwekezaji | — | — |
Pesa kutokana na ufadhili | — | — |
Mabadiliko halisi ya pesa taslimu | — | — |
Mtiririko huru wa pesa | — | — |
Kuhusu
Zeria Shinyaku Kōgyō KK is a Japanese drug manufacturer that obtained Tillotts Pharma AG.
In 1955, the Japanese Kisaku Ibu, former Yamanouchi Seiyaku executive opened a new pharmaceutical company in Tokyo under the name Zeria Yakushō Kenkyusho. In 1970, this company becomes Zeria Shinyaku Zeria Shinyaku KK.
In 1975, it built a new factory in Kumagaya in Saitama prefecture, before the main factory in Tsukuba which was constructed by Takenaka Corporation in 1988.
In 2009, the company obtained Switzerland company Tillotts Pharma AG, and began operating internationally through a large network of subsidiaries,
It manufactures and sells pharmaceuticals in Sweden, Ireland, UK, Czech Republic, Spain, Germany, France, Italy, Vietnam and Denmark. The drug itself is developed in Switzerland, Tillotts Parma.
The company owns a 6.63% share of Asuka Seiyaku, also a pharmaceutical company, other than its subsidiaries.
The main shareholder of the company is the company itself, the present president Mitsuhiro Ibu, Mitsubishi UFJ Financial Group, Custody Bank of Japan, Morinaga Milk Industry, SMBC, Mizuho Bank, Risona Bank, Aioi Nissay Dowa Insurance as of March 2023. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
22 Des 1955
Tovuti
Wafanyakazi
1,777
